GS next week FDA is hosting an Adcom to review $GSK BCMA antibody drug conjugate for late stage multiple myeloma, which is a competitor to various BCMA CAR-T $BMY $BLUE $JNJ expect the focus to be on the drug’s vision safety profile given the prior data.